Search | Médecins Sans Frontières Access Campaign

6 results found
There are 2 active filters
Clear all filters
lamivudine
pibrentasvir

6 results found

Letter |

09 August 2021

Open letter to AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C

MSF sent another open letter urging AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C in LMICs

Tags Hepatitis C hepatitis C glecaprevirpibrentasvir

Letter |

02 October 2019

Open letter to AbbVie on access to critical hepatitis C treatment – glecaprevir/pibrentasvir (G/P)

Médecins Sans Frontières (MSF) Access Campaign wrote an open letter to pharmaceutical corporation AbbVie to express our urgent need for glecaprevir/pibrentasvir (G/P) combination to treat people with hepatitis C.

Tags Hepatitis C glecaprevirpibrentasvir Medicines Patent PoolAbbVie

Technical brief |

11 March 2019

MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie for glecaprevir/pibrentasvir (G/P)

Tags Hepatitis C glecaprevirpibrentasvir Medicines Patent PoolAbbVie

Research article |

03 July 2004

Lancet: Effectiveness and safety of a generic FDC of NVP, d4T, 3TC, in HIV-1-infected adults in Cameroon

Tags HIV/AIDS HIV/AIDS antiretroviral medicinesFDCslamivudinenevirapinestavudine Cameroon

Issue brief |

16 June 2004

Two Cipla AIDS Drugs Removed from WHO Prequalification List

Tags HIV/AIDS antiretroviral medicineslamivudine WHO pre-qualification World Health OrganizationCipla

Press release |

12 December 2003

South Africa: Window of opportunity opens for South Africa to access affordable antiretrovirals

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicineslamivudinenevirapinezidovudine Boehringer IngelheimGlaxoSmithKline South Africa

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous